Bankert RB - Search Results

1

Patient immune response to tumors monitored using SCID mouse models.

Bankert RB, Chen FA, Sugiyama Y, Egilmez N. Bankert RB, et al. Immunol Invest. 2000 May;29(2):171-6. doi: 10.3109/08820130009062301. Immunol Invest. 2000. PMID: 10854186 Review. No abstract available.

2

Antitumor immune response of human peripheral blood lymphocytes coengrafted with tumor into severe combined immunodeficient mice.

Iwanuma Y, Chen FA, Egilmez NK, Takita H, Bankert RB. Iwanuma Y, et al. Among authors: bankert rb. Cancer Res. 1997 Jul 15;57(14):2937-42. Cancer Res. 1997. PMID: 9230205

3

Interleukin-12 delivered by biodegradable microspheres promotes the antitumor activity of human peripheral blood lymphocytes in a human head and neck tumor xenograft/SCID mouse model.

Kuriakose MA, Chen FA, Egilmez NK, Jong YS, Mathiowitz E, DeLacure MD, Hicks WL Jr, Loree TL, Bankert RB. Kuriakose MA, et al. Among authors: bankert rb. Head Neck. 2000 Jan;22(1):57-63. doi: 10.1002/(sici)1097-0347(200001)22:1<57::aid-hed9>3.0.co;2-k. Head Neck. 2000. PMID: 10585606

4

Growth of human tumor xenografts in SCID mice quantified using an immunoassay for tumor marker protein in serum.

Conway TF Jr, Sabel MS, Sugano M, Frelinger JG, Egilmez NK, Chen F, Bankert RB. Conway TF Jr, et al. Among authors: bankert rb. J Immunol Methods. 2000 Jan 13;233(1-2):57-65. doi: 10.1016/s0022-1759(99)00190-8. J Immunol Methods. 2000. PMID: 10648856

5

Human-SCID mouse chimeric models for the evaluation of anti-cancer therapies.

Bankert RB, Egilmez NK, Hess SD. Bankert RB, et al. Trends Immunol. 2001 Jul;22(7):386-93. doi: 10.1016/s1471-4906(01)01943-3. Trends Immunol. 2001. PMID: 11429323 Review.

6

Antitumor efficacy of a human interleukin-12 expression plasmid demonstrated in a human peripheral blood leukocyte/human lung tumor xenograft SCID mouse model.

Hess SD, Egilmez NK, Shiroko J, Bankert RB. Hess SD, et al. Among authors: bankert rb. Cancer Gene Ther. 2001 May;8(5):371-7. doi: 10.1038/sj.cgt.7700314. Cancer Gene Ther. 2001. PMID: 11477457

7

SCID mouse models to study human cancer pathogenesis and approaches to therapy: potential, limitations, and future directions.

Bankert RB, Hess SD, Egilmez NK. Bankert RB, et al. Front Biosci. 2002 Apr 1;7:c44-62. doi: 10.2741/A758. Front Biosci. 2002. PMID: 11915860 Review.

8

Human CD4+ effector T cells mediate indirect interleukin-12- and interferon-gamma-dependent suppression of autologous HLA-negative lung tumor xenografts in severe combined immunodeficient mice.

Egilmez NK, Hess SD, Chen FA, Takita H, Conway TF, Bankert RB. Egilmez NK, et al. Among authors: bankert rb. Cancer Res. 2002 May 1;62(9):2611-7. Cancer Res. 2002. PMID: 11980657

9

Tumor vaccination with cytokine-encapsulated microspheres.

Egilmez NK, Jong YS, Mathiowitz E, Bankert RB. Egilmez NK, et al. Among authors: bankert rb. Methods Mol Med. 2003;75:687-96. doi: 10.1385/1-59259-324-0:687. Methods Mol Med. 2003. PMID: 12407772 No abstract available.

10

Human CD4+ T cells present within the microenvironment of human lung tumors are mobilized by the local and sustained release of IL-12 to kill tumors in situ by indirect effects of IFN-gamma.

Hess SD, Egilmez NK, Bailey N, Anderson TM, Mathiowitz E, Bernstein SH, Bankert RB. Hess SD, et al. Among authors: bankert rb. J Immunol. 2003 Jan 1;170(1):400-12. doi: 10.4049/jimmunol.170.1.400. J Immunol. 2003. PMID: 12496425

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

141 results

Search Page

Filters